Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2741-2760 of 3,900 trials

Cemiplimab for High-Risk Skin Cancer

We are studying whether the immunotherapy Cemiplimab can help prevent cancer recurrence in patients with high-risk stage III/IV skin cancer who can undergo surgery.

Cutaneous Squamous Cell CarcinomaSurgically Resectable, High Risk Stage III/IV Cutaneous Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDermatologyOncology

Advanced Pancreatic Cancer: Gemcitabine and Nab-Paclitaxel Study

We are studying whether switching to a new treatment after initial chemotherapy helps patients with advanced pancreatic cancer live longer and feel better compared to continuing their current treatment.

Advanced Pancreatic Cancer≤3 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Desmoid Tumors: Nirogacestat Study for Women

We are studying how Nirogacestat affects ovarian function in adult premenopausal women with desmoid tumors. The trial aims to understand any ovarian toxicity and the overall safety of the treatment.

Desmoid Tumors (Aggressive Fibromatosis)1-2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Cancer Imaging: GEH200520 and GEH200521 Injections

We are testing two new injections to see if they are safe and well-tolerated in patients with cancer. This study aims to improve imaging techniques for better cancer diagnosis.

Malignant Solid Tumor>2 yearsSafety phase (I)OncologyOtolaryngology

BI 3776528: Tolerance Study in Healthy Men

We are testing how well different doses of a new medication are tolerated by healthy men. This study aims to gather important safety information for future research.

Healthy VolunteersSafety phase (I)DermatologyInternal MedicineOphthalmologyOtolaryngologyPediatricsPsychiatry

HPV Vaccine Study for Women with HPV 16/18

We are studying how the 9vHPV vaccine affects the infectivity of HPV in women who are positive for HPV types 16 and/or 18. The goal is to see if vaccination reduces the virus in cervical, anal, urine, vulvar, and oral samples.

Human Papillomavirus Infection>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Eosinophilic Esophagitis: Budesonide Dosing Study

We are comparing the effectiveness and tolerability of taking budesonide once daily versus twice daily for adults with esophagus inflammation. This study aims to see if both dosing schedules work equally well and how they affect patients' quality of life.

Eosinophilic EsophagitisConfirmation phase (III)≤5 visitsInvestigational MedicinesGastroenterologyInternal Medicine

Ulcerative Colitis: SAR442970 Study

We are investigating how effective different doses of SAR442970 are for adults with moderate to severe ulcerative colitis. The study aims to see if it can help improve symptoms and overall quality of life.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesGastroenterology

Kidney Transplant: IVIG for BKV Prevention

We are studying whether intravenous immunoglobulins can help prevent BKV viremia in kidney transplant recipients with low antibody levels. This research aims to improve outcomes for patients at risk of BKV-related complications.

Kidney Transplant and BKV Infection>2 yearsConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesNephrology

Ewing Sarcoma: Dinutuximab Beta with Chemotherapy

We are studying a new treatment combining dinutuximab beta with standard chemotherapy for patients with GD2-positive Ewing sarcoma. The goal is to find the best dose and assess how well it works in improving patient outcomes.

Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboStandard MedicinesOncologyPediatrics

New Method for Umbilical Vein Catheterization in Newborns

We are studying a new technique for umbilical vein catheterization to see if it helps newborns in circulatory arrest receive faster and more effective resuscitation. This trial compares the new method with standard practices in the delivery room.

Cardiorespiratory Arrest at Birth in Full-Term Newborns≤3 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicinePediatrics

Myelofibrosis: Roginolisib with Ruxolitinib

We are studying the safety and tolerability of roginolisib combined with ruxolitinib for patients with myelofibrosis who haven't responded to other treatments. The trial also looks at symptom improvement and changes in spleen size.

MyelofibrosisSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Fecal Incontinence: Botulinum Toxin Injections

We are studying how botulinum toxin injections may improve rectal movement in patients with fecal incontinence. The trial will also look at the treatment's effectiveness, quality of life, and tolerance after one month.

Fecal Incontinence>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Melanoma, Breast Cancer, and Head & Neck Cancer: Contrast-Enhanced Ultrasound Study

We are exploring whether contrast-enhanced ultrasound can better locate sentinel nodes during surgery compared to the current standard method. This study aims to improve detection and potentially predict if the nodes are cancerous.

Breast CancerMelanomaHead and Neck Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesGynecology and ObstetricsOncologyOtolaryngology

Acute Myeloid Leukemia: Venetoclax and Azacitidine Study

We are comparing a new treatment combination with standard chemotherapy for patients with newly diagnosed acute myeloid leukemia and NPM1 mutations. The goal is to see if this new approach is more effective and easier to tolerate.

Acute Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Grass Allergy: Vitamin D Enhanced Immunotherapy

We are studying whether combining intralymphatic immunotherapy with vitamin D helps improve allergy symptoms in people with moderate to severe grass allergies during pollen season.

Allergic Rhinitis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesAllergology

Multiple Myeloma: HDP-101 Treatment Study

We are testing a new treatment called HDP-101 for patients with relapsed or refractory multiple myeloma. The study aims to find a safe dose and evaluate how well it works.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Filgrastim for Severe Bullous Drug Eruptions

We are studying whether Filgrastim can help patients with severe drug reactions like Stevens-Johnson syndrome. The goal is to see if it slows disease progression and improves recovery compared to standard treatment alone.

Stevens Johnson SyndromeLyell Syndrome>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsInvestigational MedicinesDermatology

Tranexamic Acid for Reducing Blood Loss in Cesarean Deliveries with Placenta Previa

We are studying whether a low dose of tranexamic acid can help women with placenta previa experience less blood loss during cesarean delivery. This trial aims to improve safety and outcomes for mothers and their babies.

Placenta PreviaPostpartum Hemorrhage≤3 monthsConfirmation phase (III)Standard MedicinesGynecology and ObstetricsHematology

Multiple Myeloma: New CAR-T Cell Therapy Study

We are testing a new CAR-T cell therapy for adults with relapsed or refractory multiple myeloma who have been treated with lenalidomide. The goal is to see if it works better than standard treatments currently available.

Relapsed/Refractory Multiple Myeloma>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology